OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

← The British Oncology Pharmacy Association

2025-03-31-accounts

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION

REPORT AND ACCOUNTS

FOR THE YEAR ENDED

31[ST] MARCH 2025

REGISTERED CHARITY NO. 1065026

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

CONTENTS

Trust Information
Independent Examiner’s Report
Trustees Annual Report
Receipts and Payments Account
Statement of Assets and Liabilities		 Page
2
3
5
12
14

1

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

TRUST INFORMATION

Registered Charity No. 1065026
Trustees Robert Duncombe
Emma Foreman
Joseph Williams
Treasurers Anish Tailor
Dharmisha Chauhan
Shumi Tattersfield
Independent Examiner Barry Fine
Address c/o GBH Law,
7/8 Innovation Place
Douglas Drive
Godalming,
Surrey GU7 1JX
Bankers National Westminster Bank plc

2

INDEPENDENT EXAMINER’S REPORT TO THE TRUSTEES OF

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

I report to the trustees on my examination of the accounts for this charity for the year ended 31[st] March 2025, which are set out on pages 5 - 27.

Respective Responsibilities of the Trustees and Examiner

As the charity trustees of the charity, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 (“the Act”).

I report in respect of my examination of the Trust’s accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

It is my responsibility to:

examine the accounts under section 145 of the Charities Act,

to follow the procedures laid down in the general directions given by the Charity Commission (under section 145(5)(b)) of the Charities Act, and

to state whether particular matters have come to my attention.

Basis of Independent Examiner’s Report

My examination was carried out in accordance with the General Directions given by the Charity Commissioners. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a ‘true and fair’ view and the report is limited to those matters set out in the statement below.

3

INDEPENDENT EXAMINER’S REPORT TO THE TRUSTEES OF

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Independent Examiner’s Statement

In connection with my examination, no matter has come to my attention:

have not been met; or

Name. B. Fine FCA Address Parkgates Dated 26 January 2026 Bury New Road Prestwich Greater Manchester M25 0JW

4

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

BOPA is an unincorporated organisation governed by its constitution.

Charity Number 1065026

Administrative Details

Principal address: GBH Law, 7/8 Innovation Place, Douglas Drive, Godalming, Surrey, GU7 1JX

----- Start of picture text -----
Member Main Committee Role within BOPA
Joseph Williams Executive Chair
Vice Chair / EDI Co-
Shereen Nabhani-Gebara Executive
Chair
Co-Secretary/
Clayton Wong Executive Digital Co-Chair /
Website Manager
Co-Secretary / E&T
Michal Sladkowski Executive Co-Chair / Podcast
Lead
Dharmisha Chauhan Executive Co-Treasurer
Anish Tailor Executive Co-Treasurer
Shumi Tattersfield Executive Co-Treasurer
Pharmacy
Mollie Bishop Executive
Technician Rep
GAP Co-Chair –
Rhiannon Walters-Davies Executive
Interim Industry Rep
Symposium / IO Co-
Alice Tew Executive
Chair
Independent Sector
Anita Carlier Executive
Rep / Co Chair
New to Oncology
Sofia Dutto Executive
Rep
Diana Matthews Executive TBC
----- End of picture text -----

Structure

Members of the committee are elected for a three year term of office by the voting members through an electronic ballot. Each candidate provides a written statement in support of their application. These statements are electronically submitted to the members. The results of the election are announced at the Annual Symposium. Members can serve a maximum of two consecutive terms of office on the committee.

This committee then votes for the officers of Chair and Treasurer between themselves.

5

The association does not require any fundraising or grant-making activities. It is self-funding by members subscriptions, with additional sponsorship from the pharmaceutical industry for key projects such as e- Learning.

Decisions are made at the monthly committee meetings on behalf of the membership. The committee have several sub committees which feed back to the committee their decisions and ideas on behalf of the membership.

6

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Sub committees:

  1. Annual Symposium

  2. Education and Training

  3. Research

  4. Community and Primary Care Pharmacy

  5. Digital

  6. Guidelines, Advocacy and Publications

  7. Pharmacy Technician

  8. Workforce and Capacity

  9. Equity, Diversity, and Inclusion

Governance

Due to the nature of this charity no policies are in place to recruit and train trustees. Generally, those people elected by the members of the association are then responsible for the maintenance and safe handling of the Charity on behalf of the members.

Any decisions that require the membership to be involved in, such as national consultation documents, the document is placed on the BOPA website and emailed throughout the membership for comments to be received by the reference sub-committee who will then collate the response and return it.

The association works closely with the NHS England Cancer Area Team Pharmacists, and other relevant (oncology) pharmacy groups.

Objectives

The stated aim of BOPA is to promote excellence in the pharmaceutical care of patients with cancer through education, communication, research and innovation by an alliance of hospital, community and academic pharmacists, pharmacy technicians, those in the pharmaceutical industry and other healthcare professionals.

Public Benefit

These activities are undertaken to further the charitable purposes for the public benefit and the trustees believe that these activities satisfy the charity commissions general guidance on public benefit.

7

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Achievements and performance

The role of BOPA in supporting and provided educational and training resources has increased and the scope and breadth of the projects and advocacy roles we have been involved with has widen. In light of this we have seen our BOPA membership increasing, for example in August 2025 we had 1093 paid members, 2501 free members and 30 corporate members. Additionally, since the launch of the website in 2019, BOPA has received over 3000 networking and clinical queries. Examples of BOPA’s key achievements are described below.

Let’s Communicate Cancer

After much work the LCC 3-year review was completed in February 2025. The process involved advertising and recruiting reviewers, preparation of an SOP, talking through the review points submitted to decide which required action, implementation of the actions, reinstallation of changed elements, checking media quality of materials was maintained.

LCC development documents are gradually being transferred from Jackie to the BOPA drive. Responsibility for LCC is being handed over to the Education and Training sub-committee. A new LCC Lead Jennifer Allen is in post and is handling enquiries and progressing LCC.

Work was carried out on LCC to make the new Play Your Part materials more visible in the modules rather than solely situated on the Cancer Hub. The red flag animation videos are now in Module 1 along with series 1 of the factsheets. Other series of factsheets are situated in Modules 2 and 3 as appropriate. Material on the NHS E-learning for Health website is now out of date so negotiations between BOPA and the E-lfh teams are underway to inform users this is the case.

The LCC lead will preside over the current Royal Society Prevention for Health accreditation.

A grant has been received from Ipsen to examine the usefulness of LCC to other professions such as nursing and medicine. This work is being undertaken by the BOPA special interest group looking at community support of advanced cancer patients (CASPC).

Further work is required by all areas of BOPA to advertise and increase uptake of the valuable LCC resource.

.

The digital sub-has been very busy supporting and promoting various events with a variety of website uploads and communications from other sub-committees including:

8

The subcommittee also respond to and reply to membership and website enquiries.

Website updates:

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Research Subcommittee

The aim of the BOPA Research Committee is to lead, develop and encourage high quality oncology/haematology pharmacy practice research and thereby increasing knowledge and promoting excellence in the care of cancer patients. Our main roles include

Promoting research, audits, service evaluation and innovation amongst the BOPA membership by signposting existing resources and developing materials accessible through the BOPA website

Key achievements in 2024-2025

During the period of 24/25, we provided 3 webinars.
March 2025: Unseen and unheard: The medicine-related
needs of older people with sensory impairment (OPwSI)
April 2025: New Models of Care
September 2025: Demystifying Systematic Reviews
Future planned webinars include:
November 2025: Covidence 101
December 2025: Data extraction overview

2026: New models of care
bor
OPa>:
WEBINAR
oe		 During the period of 24/25, we provided 3 webinars.
March 2025: Unseen and unheard: The medicine-related
needs of older people with sensory impairment (OPwSI)
April 2025: New Models of Care
September 2025: Demystifying Systematic Reviews
Future planned webinars include:
November 2025: Covidence 101
December 2025: Data extraction overview

2026: New models of care
bor
OPa>:
WEBINAR
oe
PRUK/BOPA
grant
The 2023 PRUK/BOPA grant was awarded to Lisa Macleod who will
be completing a project titled: ‘A Realist Evaluation of
CloseHER2Home, a community pharmacy-led cancer treatment
pathway’.
Collaborative
Research		 A dedicated workstream has recently restructured to enhance
research collaboration across the BOPA community. This refreshed
approach aims to foster inclusive engagement and create a dynamic
platform for all members to contribute to research initiatives.

9

Supporting members in initiating, developing, and disseminating
research.
Key objectives include:
Create a database/research directory where members can
register projects and research interest
Promote collaborative working group at the BOPA symposium
Identify and overcome barriers for collaborative work e.g.
dissemination of standard data sharing agreements and
contracts
Set up a collaborative research project as a proof of concept.
We have identified a project around 'equity of access to new
treatments'
Key outcomes:

Increased engagement with research

Increased no of multi-centre abstracts to be submitted to
BOPA symposium

Increase average number of subjects per BOPA abstract
submitted		 Supporting members in initiating, developing, and disseminating
research.
Key objectives include:
Create a database/research directory where members can
register projects and research interest
Promote collaborative working group at the BOPA symposium
Identify and overcome barriers for collaborative work e.g.
dissemination of standard data sharing agreements and
contracts
Set up a collaborative research project as a proof of concept.
We have identified a project around 'equity of access to new
treatments'
Key outcomes:

Increased engagement with research

Increased no of multi-centre abstracts to be submitted to
BOPA symposium

Increase average number of subjects per BOPA abstract
submitted
Abstracts
We received 174 abstracts for the 2025 conference. Five have been
selected for Oral presentation (Plenary), 5 for the highly commented
poster presentations, 124 for posters and 40 were rejected. There
were 2 abstracts received under the service improvement and New
Models of Care category which have been invited to present as at
future My Research Webinar.
Last year’s abstract booklet published in the Journal of Oncology
Pharmacy Practice can be foundhere.
Pharmacy Practice can be found
BOPA
conference
The research stream at the BOPA conferences remains strong with
multiple sessions including presentations from Professor Christine
Bond and Dr Ruth Miller. Our focus this year is developing our
members to be better equipped to undertake research.
Advanced
Pharmacy Study
Day
We presented at the BOPA Advanced Pharmacy Study Day in Jun
25 titled_"Getting Started with Research: A Practical Guide to Begin_
_and Thrive."_Now in its second year, this well-attended event aims to
support senior pharmacists pursuing RPS Advanced Credentialing or
Consultant Pharmacist Credentialing. The study day provides
practical guidance to help attendees generate evidence for the
research pillar, a key component of the credentialing process.
Mentoring Since the creation of this expert mentorship list in Sept 2022, we
now have 29 experienced pharmacists who have volunteered to
support BOPA members to develop research projects, service
evaluations/innovation projects or audits. Check out
https://www.bopa.org.uk/research-support-list/.

10

Cancer
pharmacy
technicians		 The research subcommittee and pharmacy technician subcommittee
conducted a national survey on workforce distribution, training
received and perceived gaps to provide insight into aligned post-
registration training framework and strengthening education
pathways and work plan standardisation. We will be presenting a
poster at the BOPA conference 2025.
Future activity We are exploring ways of using AI to support with the subcommittee
activities.

11

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

The education and training team continued to deliver high quality education and training resources, key worked centered on the areas below:

----- Start of picture text -----
E-Learning ● Since the beginning of 2025 we have launched 2 more modules:
● CINV
● Multiple myeloma
● Currently in progress CLL module due to launch in November 2025
● New agreement with GCA and funding secured for 3 more modules by the end of
2025:
● Prostate
● Gastric
● Oesophageal
● Recent funding for another module for the beginning of 2026
● SOP for SME recruitment process developed and approved
● Talks with GCA with regards to developing accredited courses on leadership,
research, development
BOPA Passport ● 2400 users as of Sept 2025
● Major update of all Passport content available from August 2025
● Working with RPS for long-term endorsement of the Passport
● Working with EBMT colleagues to allow for European use
● New UK Wide Training Pack to support Passport use – launching at BOPA 2025.
2025/26 workplan
- Development of paediatric resources including POSCU module and paediatric
transplant.
-
Focus on advanced therapies.
Introduction to Cancer Over 140 attendees to an ITC event in the last year!
● Two successful courses:
● London Nov 2024 (80 delegates)
● Leeds May 2025 (64 delegates)
● NEW sessions introduced for 2025 Introduction to Haematology and Introduction to
Paediatric Oncology - great feedback!
● Planning underway for the next ITC event, likely early 2026 in Scotland
● Working with ISOPP to develop an international “Foundations in Cancer Course”
Webinars ● Successful year so far webinars with very good attendance from BOPA members.
● So far, we had 5 webinars, one of which was the International COSA, BOPA,
CAPHO, ISSOP.
● In conversation to have two more of the international webinars organised hopefully
by the end of the year.
● Two AI webinars took place in the last 2 months with 1 more to be organised in the
near future.
● New 3-part webinar series for systematic reviews to take place in
November/December with open access to non-paying members.
Advanced Practice ● Launched in 2024, the BOPA Advanced Practice Study Day for pharmacists seeking
to explore advanced roles and career development.
Study Day
● Over the past two years, we’ve welcomed more than 30 delegates
● In 2025, we introduced a modest delegate fee, yet attendance increased compared
to the inaugural. Feedback has been consistently positive, and we enhanced the
programme in year two based on delegate
● The study day offers pharmacists a unique opportunity to gain insight into advanced
practice pathways, develop professionally, and connect with peers across the UK.
----- End of picture text -----

12

● Looking ahead, we plan to continue evolving the study day to meet the needs of our
members.
Podcasts ● 9452 all-time downloads as of 26/8/25
● 42 episodes published
● Reflected on feedback from last year- peer review of journals included
● Continuing to publish one episode per month on average.
● Feedback continues to be positive
●In 2026 we would like to cover: dietetics, sexual health, menopause and much more
Lets Communicate
Cancer		 ● Handover to new clinical lead in June 2025
● Migration from eLearning for Health to NHS Learning Hub started, due to complete
Oct 2025. Note eLearning for Health content is out of date so a holding message will
be placed on the content to direct users to the Cancer Hub on the BOPA website in
the interim
● Funding sources to update eLearning for Health/NHS Learning Hub to be explored
●Contentreviewplannedfor 2026
Consultant Pharmacist
Credentialling Support		 ● BOPA poster accepted re last year’s credentialing webinar series and questionnaire.
● Proposal to set up a SIG for Cancer Credentialing Pharmacists - webinars will move
to this group, as well as advanced practice framework, support for portfolio
completion etc.
Universities Project ● Slides developed and waiting design, education and EDI review
● Currently contains 5 recordings from pharmacists from backgrounds of chief
pharmacist, charity lead, QA, private sector and ISOPP
● 2 pilot sites selected to trial presentation – one for pharmacists and another for
pharmacy technicians
● Plan for survey to be distributed to recruit BOPA members to speak at nearby
Universities

The EDI sub-committee consists of 15 members and 3 recently recruited interns. In the past 12 months, it’s been very active in delivering BOPA’s commitment to building a diverse, equitable and inclusive community for all members, non-members and patients in cancer care.

Key Achievements for the past 12 months

KeyAchievements for thepast 12 months
Clinical considerations for the safe and
inclusive prescribing for trans gender
and non-binary patient		 This work is in collaboration with
OutPatients (a charity supporting and
amplifying LGBTIQ+ voices in cancer
care).
The TRANScribing guideline is now
available on BOPA and OUTpatients
website and published in BPS official
journal
Collaborations with European Cancer
Organisation for wider exposure in Europe.
Publication TRANScribing: Clinical considerations for
safe and inclusive prescribing for
transgender and non-binary patients v2
John & Stewart have applied for a Gilead
clinical fellowship to accelerate this work
(decision expected October 2025).
John will also present this at the Pharmacy
Show and possibly at CPC North 2025 in
Manchester.

13

----- Start of picture text -----
Review of BOPA Educational Materials We are developing a checklist of EDI
considerations to guide the design of
educational materials for BOPA.
Once the checklist has been approved, we
will begin reviewing the most frequently
accessed documents as a priority and
apply the checklist to promote inclusive
language throughout BOPA’s website.
This work is being carried out in
collaboration with the E&T Subcommittee.
Re-survey of membership reception of Equity, diversity, and inclusion in oncology
the EDI engagement pharmacy practice: Everyone's business.
We have resurveyed BOPA members at
2024 conference with re-designed
questions, taken into account feedback
that we have received from the first
survey. However, the response rate was
very low (8 responses in total), and we are
working towards improving engagement
within our subcommittee.
Transatlantic collaborations: Jurga presented BOPA EDI survey results
Canada (2022), our current workstreams and her
recently published scoping review results
(Scoping review identifying interventions
that have been tested to optimise the
experience of people from ethnic minority
groups receiving systemic anticancer
therapy (SACT)) at ISOPP.
This has generated interest to work
collaboratively on several projects. Our
survey is going to be adapted and used to
gather views of cancer pharmacy
workforce in Canada, this will generate
additional publications with BOPA being
acknowledged as a collaborator.
Jurga has joined ISOPP EDI
subcommittee in 2025.
Transatlantic collaborations: We had Mo Adedipe presenting at one of
USA our EDI meetings and we are building
links to work together on future research
projects to yield meaningful impact.
Transatlantic collaborations: Pascale presented Trans-cribing
Australia guidelines. Started collaboration with
----- End of picture text -----

14

Stewart and CEO Prof Dorothy Keefe to
introduce the guidelines in the ‘optimal
care pathway’.
Interest from Gilead Australia on TRANS-
cribing guideline
National and international Visibility Nordic Social Pharmacy Conference –
Shereen presented qualitative work on
diverse patient experiences (June 2025,
Glasgow)
Collaboration with Research
Subcommittee		 BOPA research committee is reviewing
the process of supporting poster
presenters at conferences to carry on
with their research and start building
collaborations between large and small
Trusts where similar interests in research
exists, thus enabling junior researchers to
build their research portfolio and grow
number of publications.
Key Performance Indicators (KPI)
taskforce		 Currently, BOPA does not have a set of
Key Performance Indicators (KPIs)
aligned with its strategic pillars or with
standard EDI KPIs used across industry.
As a result, many projects are
progressing in directions shaped by
personal interest rather than
organisational priorities. For the next year
ahead, we aim to establish clear KPI’s,
that will enable:

Differentiation between projects
aligned with BOPA’s strategic aims
and those that are more
individual/clinical in nature.

Internal and external
benchmarking for performance
review and reporting.

Greater organisational
accountability with tangible outputs
and outcomes (e.g., conference
exposure, collaborations,
publications).
We have already created a dedicated
taskforce to develop and oversee BOPA
KPIs, ensuring focus on a small number
of strong, long-term projects,

15

----- Start of picture text -----
complemented by achievable shorter-
term initiatives. This will strengthen
accountability, align activity with strategy,
and support BOPA’s growth as a
professional organisation.
Kingston University MPharm student EDI related projects:
projects: 1. Inclusive patient care consultation
framework for cancer patient’s
publications in progress (minority ethnic
groups, elderly, physical disability and
neurodiversity) (Samira and Wanauscha)
2. Inclusive patient care consultation
framework piloting in practice at the RMH.
(Karman and Iqra)
3. Intersectionality awareness in
healthcare professionals
4. Inclusive consultations in learning
disability
5.BOPA Subcommittee diversity audit
6. Virtual pharmacy clinic pilot for
families of children with cancer
(collaboration with Larsen’s Pride and
GOSH)
Conference updates Three students have been accepted for
Posters at BOPA 2025 conference
presenting EDI research
Samira, Wanauscha, and Soonia Jakiny
This year we have asked all the
presenters in the conference to include a
slide or two of how their work is adapting
the EDI framework.
We have decided to bring in the EDI
award for the next conference (2026)
EDI stand rota to be staffed at BOPA
2025 conference
Policy & Advocacy 1.Subcommittee to sign joint letter to
Secretary of State (re: 10-year cancer
plan)
2.BOPA statement for the HRA inclusion
and diversity Pilot guidance
Interns We have recruited 3 interns to help with
current EDI workstreams: Samuel, Keira
and Aini.
----- End of picture text -----

16

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

This was another productive year for the GAP members engaged in a variety of projects covering the full range of BOPA activities. To aide committee members support projects which impact on pharmacy staff working in cancer services, the committee has updated its terms of reference to better reflect the evolving role of pharmacy staff and their role in supporting patients with cancer. We will continue to provide governance oversight, both within BOPA ensuring clarity and accountability for the membership, and for BOPA’s engagement with the outside organisations, ensuring that collaboration represent the best interests of BOPA, its membership and the wider oncology pharmacy profession. We continue to advocate for the role of pharmacy professionals within cancer services and promote continuing excellent work undertaken by BOPA and its members. We will also continue to publish position statements on behalf of the BOPA membership, ensuring that we speak as one body on areas of critical importance to oncology pharmacy, providing support and guidance as needed.

A summary of the activities of the committee are summarised below:

UK Pharmacy Research Advisory Board (UK PRAG)

In November GAP members contributed to the content of the UK PRAG groups pharmacy research strategy seeking to further embed the role of clinical-academia and research capacity within the workforce.

UKSB – IT policy

GAP members have played a key role in reviewing the latest update of the national UK SACT Board intrathecal policy. Members have helped to ensure that this policy is reflective of changes to provision of IT chemotherapy, challenging outdated practices and ensuring that patient safety is maintained through clear and evidence-based practice.

UKSB – hypersensitivity guidance

In May members have helped to review and contribute to the UK SACT board hypersensitivity to chemotherapy management guidance. This has helped to ensure that national guidelines reflected best practice principles.

Initial standards for pharmacy technician verification

In April GAP collaborated with the pharmacy technician committee to produce initial draft guidance regarding the potential role of pharmacy technicians in verification. This highlighted several areas of good practice which has been developed by early adopter sites for wider consideration.

UKSB Standardisation of SACT reviews

In June members helped to review the initial UK SACT board guidance regarding standardisation of SACT reviews by non-medical healthcare professionals. This ongoing work has involved extensive collaboration between GAP members, the BOPA exec, consultant pharmacist group and UK SACT board. Given the importance of this development to BOPA members working in advanced practice roles reviewing patients GAP have worked to ensure that this guidance supports the safe and effective practice of its members.

17

Develop guidance for BOPA endorsement of training programmes developed by external bodies

GAP have worked alongside the education and training committee to ensure a consistent approach to requests for endorsement of training programmes developed by external bodies. This guidance provides clarity for BOPA and its members as well as consistency for external bodies seeking to collaborate with BOPA.

Support and Collaborations

Supported the establishment of the new BOPA AI specialist interest group seeking to define the role of this emerging technology within oncology pharmacy practice.

Supported the NHS England Aseptics Infusion Board as part of workforce strategy developments to ensure rationale use of aseptic manufacturing capacity.

Conference Presentations

The GAP committee has worked to support BOPA members to present at a range of conferences within the past 12 months including, the pharmacy show, HSJ cancer forum, the RPS conference and CPC north.

Changes to GAP Co-chairs in 2025/2026

After supporting the work of the GAP committee as co-chair for 8 years Rhiannon is stepping down. The GAP members would like to thank her for her tireless work in driving forward changes to national policy that GAP members have contributed to. Rhiannon has helped to steer BOPA and the oncology pharmacy profession through a number of challenges during her tenure (Covid) and always acted with commendable attention to detail and good humour. Rhiannon will be replaced by David Mace who will assume a role as co-chair in November 2025. After six years of dedicated service as co-chair, Andy is stepping down to pursue an exciting new chapter—a PhD. Andy’s leadership, insight, unwavering commitment and pragmatism have made a lasting impact, and GAP are very grateful for his contribution. Andy will be replaced by Jessica Pealing from January 2026.

Both Rhiannon and Andy will remain as members of the GAP committee and help to support the new chairs as they development within the role. GAP are delighted to welcome David and Jess into their new roles

18

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

The conference sub-committee had another productive year and delivered another successful conference in Birmingham 2024, alongside the executive committee.

One significant difference to previous conferences, was the inclusion of an award ceremony at the Gala Dinner. Winners of the research awards, BOPA fellowship and the new Above and Beyond Award were recognised at this ceremony, whereas previously is at been on the Sunday morning. There was overwhelming positive feedback about this, and so the subcommittee have made the decision to repeat this at the Belfast Conference.

We have also responded to feedback ensuring we make the conference as welcoming as possible for ‘first timers’ and those coming on their own. We have several things planned to improve this in Belfast. See the conference video and all information on the 2024 conference here: 27th Annual BOPA Conference – Birmingham 2024 - BOPA

2024 Birmingham Stats:

Benefit to the public

As an organisation promoting excellence in the pharmaceutical care of patients with cancer, BOPA provides up-to-date resources for academic pharmacists, pharmacy technicians, those in the pharmaceutical industry and other healthcare professionals. Thereby promoting up-to-date safe and efficient practice through education, training and through participating in collaborative research both nationally and at a global level. In 2025 BOPA also created a Patient and Public Involvement Specialist - Advisory Group (Cancer Community Partners Group - Cancer Community Partners Advisory Group BOPA)

19

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Activities undertaken to benefit the public

  1. Let’s Communicate Cancer project. The aim of the project is to educate and up-skill community pharmacists to engage with the public in the community setting with confidence and developing a knowledge base around cancer and its treatments.

  2. The development of podcast to provide education and training using a new technology platform.

  3. Annual BOPA symposium: Providing educational sessions to our members, on areas such as clinical management in cancer, good practice research methods (e.g., engaging with patients, public and carers) and scientific updates. This ensures our members have the knowledge, skills, and confidence to manage and work with cancer patients at their place of work.

  4. The publication of the “Clinical considerations for the safe and inclusive prescribing for trans gender and non-binary patients”. This work was completed in collaboration with OutPatients (a charity supporting and amplifying LGBTIQ+ voices in cancer care).

  5. BOPA Submission for the National Cancer Plan for England 2025 – Call for Evidence - BOPA Submission for the National Cancer Plan for England 2025 - Call for Evidence - BOPAPatient and Public Involvement Specialist Advisory Group (Cancer Community Partners Group - Cancer Community Partners Advisory Group - BOPA

20

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Financial review

Trustees’/members’ expenses for services

As a charitable organisation members and the three trustees are eligible for travel expenses, team building exercises and hotel accommodation. In this financial year the total cost is £1,999.

Reserve accounts

The Charity holds cash funds of £119,859, split between Nat West Bank accounts and a Scottish Widows account, of which £68,941 are restricted.

The reason for holding these reserves is:

  1. In the event of a reduction in income the charity will be able to continue to provide its core functions and cover all existing fixed costs and commitments e.g., website maintenance.

  2. The charity provides an annual educational event. In the normal course of events these meetings are at least “break even”. However, there is the risk that the income for this meeting may be below the costs associated with running the meeting, and BOPA will be liable for this shortfall.

Summary of accounts

The total income received was £143,086 and the total payments made were £186,522.

This gave BOPA net expenditure of £43,436 for the year, and total assets/funds of £119,859, split between unrestricted funds of £50,918 and restricted funds of £68,941.

21

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Plans for the future

  1. To continue to collaborate with national and international (oncology) pharmacy groups to maintain and consolidate its professional and advocacy role.

  2. During 2025-2026 BOPA will continue to develop and provide high quality education and training materials for all their members.

  3. BOPA is also keen to develop and continue educational scholarships for its members and to fund research into Pharmacy Practice Research where there is a focus on cancer.

  4. The BOPA 2025 symposium will be delivered as a face-to-face in London, England.

  5. Continue collaboration with Specialist Pharmacy Groups and Professional Leadership Bodies to work together to have a unified Pharmacy voice within the UK.

  6. Continue with strategy development within individual Subcommittees after vision publication - About BOPA - BOPA

22

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Declaration

Signed on behalf of the charity’s trustees

2“
Signature 2“
Full Name Mr Joseph Williams …………..…………………………………
Position Chair ………………………………………………………………
Date 19 January 2026
Signature
Full Name MsShereen Nabhani-Gebara…..………………………………………….
Position Vice -Chair ………………………………………………………………
Date 19 January 2026
Signature
Full Name Mr Rob Duncombe ………..…………………………………….
Position BOPA Trustee ……………………………………………………
Date 19 January 2026

23

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

24

Insurance Online banking Secretariat Audit research Education - LCC Educational Education - intro to oncology Education - podcast Education - webinar Life in a day/Day in the life BOPA grants Grants Legalfees Media Abstract SACT passport Sundry Prize money Net payments/receipts Cash funds brought forward Cash funds carried forward 6,385 15,212 8,567 2,200 2,579 3,978 10,214 25,875 553 114,377 -20,291 71,209 50,918 25 57,139 9,486 654 4,866 72,145 -23,145 92,086 68,941 0 0 6,385 72,351 18,053 2,200 0 0 654 4,866 2,579 3,978 10,214 25,875 553 0 186,522 247 80 2,010 0 69,005 10,893 24,501 3,605 1,135 12,906 12,760 0 3,120 500 2,675 44,455 35 2,000 257,186 -43,436 163,295 119,859 -90,959 254,254 163,295

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

The Accounts were approved by the Committee on 19 January 2026

Joseph Williams - Chair

Shereen Nabhani-Gebara - Vice-Chair

Dharmisha Chauhan Co-Treasurer

26

Causalor. Anish Tailor Co-Treasurer 27